294 related articles for article (PubMed ID: 24713986)
41. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
[TBL] [Abstract][Full Text] [Related]
42. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
43. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
44. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.
Huff V; Reeve AE; Leppert M; Strong LC; Douglass EC; Geiser CF; Li FP; Meadows A; Callen DF; Lenoir G
Cancer Res; 1992 Nov; 52(21):6117-20. PubMed ID: 1356625
[TBL] [Abstract][Full Text] [Related]
45. Nephrogenic rests and renal abnormalities in Brachmann-de Lange syndrome.
Charles AK; Porter HJ; Sams V; Lunt P
Pediatr Pathol Lab Med; 1997; 17(2):209-19. PubMed ID: 9086528
[TBL] [Abstract][Full Text] [Related]
46. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
[TBL] [Abstract][Full Text] [Related]
47. Precursor lesions of Wilms' tumor in Indian children: a multiinstitutional study.
Mishra K; Mathur M; Logani KB; Kakkar N; Krishna A
Cancer; 1998 Nov; 83(10):2228-32. PubMed ID: 9827730
[TBL] [Abstract][Full Text] [Related]
48. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
49. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.
Breslow NE; Beckwith JB; Perlman EJ; Reeve AE
Pediatr Blood Cancer; 2006 Sep; 47(3):260-7. PubMed ID: 16700047
[TBL] [Abstract][Full Text] [Related]
50. Cytogenetically unrelated clones in different histologic components of a Wilms tumor.
Dolan M; Mascotti K
Cancer Genet Cytogenet; 2005 May; 159(1):63-8. PubMed ID: 15860360
[TBL] [Abstract][Full Text] [Related]
51. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
52. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
Ramani P; Cowell JK
J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
[TBL] [Abstract][Full Text] [Related]
53. Renal pathology in WAGR syndrome.
Ariel I; Abeliovich D; Bar-ziv J; Hochberg A
Pediatr Pathol Lab Med; 1996; 16(6):1013-21. PubMed ID: 9025899
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience.
Hol JA; Jongmans MCJ; Sudour-Bonnange H; RamÃrez-Villar GL; Chowdhury T; Rechnitzer C; Pal N; Schleiermacher G; Karow A; Kuiper RP; de Camargo B; Avcin S; Redzic D; Wachtel A; Segers H; Vujanic GM; van Tinteren H; Bergeron C; Pritchard-Jones K; Graf N; van den Heuvel-Eibrink MM;
Cancer; 2021 Feb; 127(4):628-638. PubMed ID: 33146894
[TBL] [Abstract][Full Text] [Related]
55. Methylation Statuses of H19DMR and KvDMR at WT2 in Wilms Tumors in Taiwan.
Lu MY; Wang WC; Hou TC; Kuo CY; Lai YC
Pathol Oncol Res; 2020 Oct; 26(4):2153-2159. PubMed ID: 32157637
[TBL] [Abstract][Full Text] [Related]
56. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Yun K; Molenaar AJ; Fiedler AM; Mark AJ; Eccles MR; Becroft DM; Reeve AE
Lab Invest; 1993 Nov; 69(5):603-15. PubMed ID: 7504120
[TBL] [Abstract][Full Text] [Related]
57. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
58. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
59. A clinical overview of WT1 gene mutations.
Little M; Wells C
Hum Mutat; 1997; 9(3):209-25. PubMed ID: 9090524
[TBL] [Abstract][Full Text] [Related]
60. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
